MedTrace Logo

GS Regimen as the First-line Chemotherapy in Chinese Advanced PC Patients

NCT03869294 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2020-03-04

No results posted yet for this study

Summary

Gemcitabine plus S-1 (GS) prolonged progression-free survival (PFS) and greatly improved objective response rate (ORR) as well as disease control rate (DCR) of Asian patients with locally advanced and metastatic pancreatic cancer (PC). However, limited data of GS regimen exist on the efficacy and safety in the treatment of Chinese patients with advanced PC. To assess the efficacy and safety of gemcitabine plus S-1 (GS regimen) as the first-line chemotherapy in Chinese patients with advanced PC, we designed this prospective study.

Conditions

Interventions

DRUG

GS

Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03869294 on ClinicalTrials.gov